|[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]|
FDA approves drug to reduce risk of preterm birth in at-risk pregnant women
Fri, 04 Feb 2011 07:14:00 -0600
The U.S. Food and Drug Administration today approved Makena (hydroxyprogesterone caproate) injection to reduce the risk of preterm delivery before 37 weeks of pregnancy, in pregnant women with a history of at least one spontaneous preterm birth.
Manage your FDA Subscriptions:
U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420